Reviews/Dry Eye Disease Treatment/Cyclosporine increases Schirmer test scores
Cyclosporine · DED-CYC-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Several separate studies across different countries found that tear production, measured by the Schirmer test, went up after patients started 0.05% cyclosporine eye drops ([1],[2],[5],[8],[12],[17]). In most of these studies everyone received the drug and there was no untreated comparison group, and patients were also using other lubricating eye drops at the same time, so the rise cannot be pinned on cyclosporine alone. The one study that compared the drug against a dummy (vehicle) drop [9] did find a tear-production advantage, but only at one time point (week 4) and not at weeks 2 or 8. In a study that compared the drug against a lubricant [14], the lubricant actually trended slightly better on tear production. So the direction of the effect is consistent across studies, but clean controlled proof that cyclosporine itself drives the Schirmer rise is thin.
Across independent randomized and cohort studies, 0.05% cyclosporine arms showed Schirmer increases from baseline: [1] (5 mm and 4 mm; P<0.001), [2] at 32 weeks, [5] (35.1% of patients achieved ≥5 mm improvement and 18.9% achieved ≥10 mm), [8] at 3 months, [12] at 3 months postoperatively, [17], and [3] after 8 weeks. One vehicle-controlled trial [9] found the 0.05% arm improved the Schirmer test versus vehicle at week 4 (P=0.035). The studies span multiple countries and separate centres and match the claim's scope of 0.05%, Schirmer, and DED. Schirmer is generally a secondary endpoint and the reported magnitude is modest. The contested point: The division is whether the consistent baseline improvement reflects cyclosporine itself or concurrent lubricant use and regression in uncontrolled single-arm follow-up ([1],[7],[11]). The only clean vehicle comparison [9] separated from vehicle on Schirmer at week 4 only, with no sustained separation at weeks 2 or 8, and a lubricant comparator trended better than cyclosporine in [14].
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Most positive Schirmer data are within-group improvement over baseline while patients concurrently used artificial tears/lubricants ([1] CMC 6x/day, [11] hyaluronate combo, [7] loteprednol), so a rise does not isolate a 0.05% CsA effect.
The only vehicle-controlled 0.05% RCT [9] found the Schirmer benefit at week 4 only (P=0.035), with no sustained separation at weeks 2 or 8, undermining a general increase claim.
Where it remains uncertain. Most gains are within-group under concurrent artificial tears ([1],[11]), the controlled effect in [9] appeared only at week 4, and a 0.15% sodium hyaluronate comparator trended better on Schirmer in [14].
Aleatory
Schirmer is a highly variable measure prone to regression to the mean in single-arm follow-up ([5],[7]), so apparent gains can reflect measurement variability.
Epistemic
Only [9] tests 0.05% against vehicle on Schirmer; most studies are single-arm or active-comparator ([1],[2],[3],[5],[8],[12],[17]), leaving the drug-specific effect unmeasured.
Inferential
[9]'s vehicle separation appeared only at week 4; inferring a general, durable Schirmer increase extends beyond the one controlled data point.
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT showing significant Schirmer improvement over baseline in both 0.05% CsA arms.
“Schirmer test - 5 mm, 4 mm (P < 0.001)”
Panel auditInternal validity: medium · scope of inference: Moderate-to-severe dry eye disease treated with 0.05% cyclosporine (plus lubricant) over 12 weeks.Key limitations: no vehicle control · concomitant lubricant confounds effect · within-group before/after
0.05% CsA arm Schirmer improvement sustained to 32 weeks.
“The TJO-087 and CsA0.05% groups showed significant improvement in OSDI, TBUT, ocular surface staining, and Schirmer test scores at 32 weeks from baseline.”
Panel auditInternal validity: medium · scope of inference: Moderate-to-severe dry eye disease treated with conventional 0.05% CsA twice daily over 32 weeks.Key limitations: no vehicle control · within-group before/after for 0.05% arm
Conventional 0.05% CsA: Schirmer test I (STI) improved after 8 weeks.
“In Group 1 (conventional cyclosporine), LMT, MGS, and TBUT improved significantly after 4wk, whereas CS, CI, STI, and LLT improved significantly after 8wk, and OSDI at 12wk.”
Panel auditInternal validity: medium · scope of inference: Dry eye syndrome with meibomian gland dysfunction treated with conventional 0.05% CsA over 12 weeks.Key limitations: small sample per arm · MGD-specific population · control also received treatment for other signs
The 0.05% nanoemulsion group showed consistent statistically significant Schirmer improvement in the intergroup comparison against diquafosol.
Panel auditInternal validity: medium · scope of inference: Dry eye treated with 0.05% cyclosporine nanoemulsion over 12 weeks, benchmarked against diquafosol.Key limitations: nanoemulsion formulation · Schirmer result reported only for CN vs DQ · no vehicle arm
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent directional primary evidence plus a positive but transient vehicle-controlled signal supports a modest increase claim while confounding and weak controlled confirmation prevent a higher tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Vehicle-controlled Schirmer effect of 0.05%. Only [9] tests 0.05% against vehicle on Schirmer, and only at week 4. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Multicentre vehicle-controlled RCT with Schirmer as a prespecified primary endpoint measured at repeated timepoints.
Open question: Does 0.05% cyclosporine increase Schirmer scores versus vehicle at more than one timepoint? Why it is still open: The sole vehicle-controlled 0.05% trial [9] separated from vehicle on Schirmer only at week 4, not weeks 2 or 8.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19